Search The Medical Knowledge Base

Drug Details

PANCREX V FORTE TABLETS

• Drug Class Description
  Pancreatic enzymes.
• Generic Name
  Pancreatin
• Presentation
  Tablets
• Description
  Pancrex V Forte Tablets
• Indications
  

  Pancrex is used to compensate for reduced intestinal enzyme activity in pancreatic deficiency states. It is indicated for the treatment of fibrocystic disease of the pancreas (cystic fibrosis), chronic pancreatitis and pancreatic steatorrhoea following pancreatectomy. It may also be indicated following gastrectomy as an aid to digestion.

• Adult Dosage
  

  Dosage should be adjusted according to the needs of the individual patient and the amount and type of food consumed.

  The following dosage ranges provide a suitable basis for adjustment.

  Adults, the Elderly, and Children

  6 - 10 tablets before each snack or meal, swallowed whole

• Child Dosage
  Pancrex V Capsules: Infants, contents of 1 - 2 capsules mixed with feeds; older children, same as adult. Pancrex V Capsules '125': Neonates: 1 - 2 capsules with feeds. Pancrex V Powder: New born infants, 0.25g - 0.5g with each feed.
• Contra Indications
  

  Hypersensitivity to the active ingredient (porcine pancreatin) or any of the excipients.

• Special Precautions
  

  Unsuitable for people with lactase insufficiency, galactosaemia or glucose/galactose malabsorption syndrome.

  Variations in response to treatment may be due to enteric coating. It is possible that some irritation of the skin of the mouth may occur if tablets are chewed or preparations retained in the mouth. Irritation of the anus may also occur. A barrier cream may prevent this local irritation.

• Adverse Drug Reactions
  

  Rare cases of hyperuricosuria and hyperuricaemia have been reported when extremely high doses of pancreatin have been taken.

  Strictures of the ileo-caecum and large bowel, and colitis, have been reported in children with cystic fibrosis taking high doses of pancreatic enzyme supplements. To date Pancrex and Pancrex V presentations have not been implicated in the development of colonic damage. However unusual abdominal symptoms or changes in abdominal symptoms should be reviewed to exclude the possibility of colonic damage especially if the patient is taking in excess of 10,000 units/kg/day of lipase.